Karabajakian, A., et al., Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncology 119 (2021) 10568
Dora, D., et al. Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-State Neuroendocrine-High and -Low Small Cell Lung Cancer. Biology 2021, 10,502:2-25
Download pdf 1.4MB
View External Link
Sanegre,. S., et al. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. Front. Cell Dev. Biol., 03 June 2021 | https://doi.org/10.3389/fcell.2021.670185
Lynch, K. T., et al. IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. The American Journal of Surgical Pathology: June 2021 (45) 6: 787-795 doi: 10.1097/PAS.0000000000001622
Kumar, G., et al. Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice. Neoplasia 23(6),6 JUN 2021, 574-583. https://doi.org/10.1016/j.neo.2021.05.010
Ntala, C., et al. Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis. European Urology Open Science 29 (2021) 19-29. https://doi.org/10.1016/j.euros.2021.05.001
Guerrero-Zotano, A., et al. Plk1 expression & efficacy of Palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03). Cancer Res February 15 2021 (81) (4 Supplement) PS2-01; DOI: 10.1158/1538-7445.SABCS20-PS2-01
Sinnberg, T., et al. IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19. medRxiv preprint doi: https://doi.org/10.1101/2021.02.02.21250940 this version posted Feb 5, 2020.
Servetto, A., et al. A review of the use of Next Generation Sequencing methodologies to identify biomarkers of resistance to CKK4/6 inhibitors in ER+/HER2-breast cancer. Science Direct December 2020 DEC 9, 103191
Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.
Page last updated March 13, 2023